Role of intestinal myofibroblasts in HIV-Associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy

AIDS

Volumn 29, Issue 8, 2015, Pages 877-888

  Asmuth, David M ^a   Pinchuk, Irina V ^b   Wu, Jian ^a   Vargas, Gracie ^b   Chen, Xiaoli ^a   Mann, Surinder ^a   Albanese, Anthony ^c   Ma, Zhong Min ^d   Saroufeem, Ramez ^a   Melcher, Gregory P ^a   Cancio, Paolo Troia ^a   Torok, Natalie J ^a   Miller, Christopher J ^a,d   Powell, Don W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Veteran Administration Northern California Health System   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

collagen A, gut Associated lymphoid tissue, HIV, immune reconstitution, intestinal fibrosis, intestinal myofibroblasts, lipopolysaccharide, tissue growth factor beta, Toll like receptor 4

Indexed keywords

CD4 ANTIGEN; COLLAGEN; EMTRICITABINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; RALTEGRAVIR; TENOFOVIR; THY 1 MEMBRANE GLYCOPROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATIONAL STUDY; DUODENUM; DUODENUM BIOPSY; DUODENUM MUCOSA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INTESTINAL FIBROSIS; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA; LYMPHOID ORGAN; MALE; MYOFIBROBLAST; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STROMA CELL; TISSUE GROWTH; BLOOD; CD4 LYMPHOCYTE COUNT; CYTOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; CD4 LYMPHOCYTE COUNT; COLLAGEN; DUODENUM; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MYOFIBROBLASTS; TOLL-LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 85003048335     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000636     Document Type: Article

References (77)

1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17 26.
2. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130 1139.
3. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27 34.
4. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-Term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72 77.
5. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 3Clin Infect Dis 2009; 48:350 361.
6. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al. Limited immune restoration after 3 years suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859 1866.
7. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4R cell count restoration in HIV-infected patients receiving long-Term antiretroviral treatment. Clin Infect Dis 2009; 48:787 794.
8. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, et al. Poor initial CD4R recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48:541 546.
9. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006; 20:371 377.
10. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, et al. Long-Term mortality in HIV positive individuals virally suppressed for more than three years with incomplete CD4 recovery. Clin Infect Dis 2014; 58:1312 1321.
11. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. Low CD4R T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435 447.
12. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723 1735.
13. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143 2153.
14. Reekie J, Kosa C, Engsig F, Monforte A, Wiercinska-Drapalo A, Domingo P, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116:5306 5315.
15. Autran B, Kinloch-de Loes S, Katlama C. Therapeutic immunization in HIV infection. Curr Opin HIV AIDS 2006; 1:323 329.
16. Gutierrez C, Diaz L, Vallejo A, Hernandez-Novoa B, Abad M, Madrid N, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 2011; 6:e27864.
17. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-Treated, HIV-infected patients with a suboptimal CD4R T cell response. J Infect Dis 2011; 203:960 968.
18. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548 1559.
19. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304 6314.
20. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, et al. Effect of baseline-and treatmentrelated factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 3J Acquir Immune Defic Syndr 2006; 42: 426 434.
21. Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brenchley J, Fox C, et al. Evaluation of the pathogenesis of decreasing CD4(R) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 2009; 199:1648 1656.
22. Diaz A, Alos L, Leon A, Mozos A, Caballero M, Martinez A, et al. Factors associated with collagen deposition in lymphoid tissue in long-Term treated HIV-infected patients. AIDS 2010; 24:2029 2039.
23. Schacker TW, Brenchley JM, Beilman GJ, Reilly C, Pambuccian SE, Taylor J, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4R T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13:556 560.
24. Estes JD, Haase AT, Schacker TW. The role of collagen deposition in depleting CD4R T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol 2008; 20:181 186.
25. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998 1008.
26. Asmuth DM, Ma ZM, Mann S, Knight TH, Yotter T, Albanese A, et al. Gastrointestinal-Associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus nonnucleoside reverse transcriptase inhibitor-based regimens. AIDS 2012; 26:1625 1634.
27. Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456 464.
28. Hayes TL, Asmuth DM, Critchfield JW, Knight TH, McLaughlin BE, Yotter T, et al. Impact of highly active antiretroviral therapy initiation on CD4(R) T-cell repopulation in duodenal and rectal mucosa. AIDS 2013; 27:867 877.
29. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006; 3:e484.
30. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365 1371.
31. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-Treated HIV infection. J Infect Dis 2009; 199:1177 1185.
32. Merlini E, Bai F, Bellistri GM, Tincati C, d Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011; 6:e18580.
33. Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr 2011; 57:363 370.
34. Canary LA, Vinton CL, Morcock DR, Pierce JB, Estes JD, Brenchley JM, et al. Rate of AIDS progression is associated with gastrointestinal dysfunction in simian immunodeficiency virus-infected pigtail macaques. J Immunol 2013; 190:2959 2965.
35. Saada JI, Pinchuk IV, Barrera CA, Adegboyega PA, Suarez G, Mifflin RC, et al. Subepithelial myofibroblasts are novel nonprofessional APCs in the human colonic mucosa. J Immunol 2006; 177:5968 5979.
36. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170:1807 1816.
37. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB, Myofibroblasts II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999; 277:C183 C201.
38. Pinchuk IV, Beswick EJ, Saada JI, Suarez G, Winston J, Mifflin RC, et al. Monocyte chemoattractant protein-1 production by intestinal myofibroblasts in response to staphylococcal enterotoxin a: relevance to staphylococcal enterotoxigenic disease. J Immunol 2007; 178:8097 8106.
39. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 2003; 124:1866 1878.
40. Owens BM, Steevels TA, Dudek M, Walcott D, Sun MY, Mayer A, et al. CD90(R) stromal cells are non-professional innate immune effectors of the human colonic mucosa. Front Immunol 2013; 4:307.
41. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200:500 503.
42. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127:526 537.
43. Mifflin RC, Pinchuk IV, Saada JI, Powell DW. Intestinal myofibroblasts: Targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol 2011; 300:G684 G696.
44. Pinchuk IV, Mifflin RC, Saada JI, Powell DW. Intestinal mesenchymal cells. Curr Gastroenterol Rep 2010; 12:310 318.
45. Powell DW, Pinchuk IV, Saada JI, Chen X, Mifflin RC. Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol 2011; 73:213 237.
46. Rieder F, Fiocchi C. Intestinal fibrosis in IBD: A dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009; 6:228 235.
47. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-Associated lymphoid tissue despite long-Term antiretroviral therapy. J Infect Dis 2008; 197:714 720.
48. Santos RM, Norton P, Degli Esposti S, Zern MA. TGF-beta isoforms in alcoholic liver disease. J Gastroenterol 1998; 33:383 389.
49. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43:435 443.
50. Mahida YR, Beltinger J, Makh S, Goke M, Gray T, Podolsky DK, et al. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and-Am J Physiol 1997; 273:G1341 G1348.
51. Pinchuk IV, Saada JI, Beswick EJ, Boya G, Qiu SM, Mifflin RC, et al. PD-1 ligand expression by human colonic myofibroblasts/ fibroblasts regulates CD4R T-cell activity. Gastroenterology 2008; 135:1228 12371237.
52. Gong B, Sun J, Vargas G, Chang Q, Xu Y, Srivastava D, et al. Nonlinear imaging study of extracellular matrix in chemicalinduced, developmental dissecting aortic aneurysm: evidence for defective collagen type III. Birth Defects Res A Clin Mol Teratol 2008; 82:16 24.
53. Vargas G, Shilagard T, Ho KH, McCammon S. Multiphoton autofluorescence microscopy and second harmonic generation microscopy of oral epithelial neoplasms. Conf Proc IEEE Eng Med Biol Soc 2009; 2009:6311 6313.
54. Campagnola PJ, Millard AC, Terasaki M, Hoppe PE, Malone CJ, Mohler WA. Three-dimensional high-resolution second-harmonic generation imaging of endogenous structural proteins in biological tissues. Biophys J 2002; 82:493 508.
55. Li T, Wu N, Dai Y, Qiu Z, Han Y, Xie J, et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-Term antiretroviral therapy. Clin Infect Dis 2011; 53:944 951.
56. Allers K, Bosel D, Epple HJ, Karcher H, Schmidt W, Kunkel D, et al. Effect of age on the CD4R T cell impairment in HIVinfected persons without and with cART. J Acquir Immune Defic Syndr 2014; 66:7 15.
57. Rieder F. The gut microbiome in intestinal fibrosis: environmental protector or provocateur? Sci Transl Med 2013; 5:190s110.
58. Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl 2014.
59. Du S, Li H, Cui Y, Yang L, Wu J, Huang H, et al. Houttuynia cordata inhibits lipopolysaccharide-induced rapid pulmonary fibrosis by up-regulating IFN-gamma and inhibiting the TGFbeta1/ Smad pathway. Int Immunopharmacol 2012; 13:331 340.
60. Klase ZO, Deleage A, Mudd C, Quinones JC, Schwartzman M, Klatt E, et al. Dysbiotic bacterial translocate in progressive SIV infection. Mucosal Immunol 20doi: 10.1038/mi.2014.1[Epub ahead of print].
61. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol 2014; 7:983 994.
62. Asmuth DM, Ma ZM, Albanese A, Sandler NG, Devaraj S, Knight TH, et al. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS 2013; 27:2207 2217.
63. Klatt NR, Canary LA, Sun X, Vinton CL, Funderburg NT, Morcock DR, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013; 123:903 907.
64. Cumont MC, Monceaux V, Viollet L, Lay S, Parker R, Hurtrel B, et al. TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death Differ 2007; 14:1747 1758.
65. Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007; 195:551 561.
66. Petitjean G, Chevalier MF, Tibaoui F, Didier C, Manea ME, Liovat AS, et al. Level of double negative T cells, which produce TGF-beta and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. AIDS 2012; 26:139 148.
67. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients. Viral Immunol 2004; 17:109 113.
68. Carneiro TX, Pacheco JT, Xavier MB, Quaresma JA. Tissue expression of TGF-beta1 in uterine cervical samples from HIV/AIDS patients. Microb Pathog 2012; 53:44 48.
69. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB, Myofibroblasts I. Paracrine cells important in health and disease. Am J Physiol 1999; 277:C1 C9.
70. Fuster D, Tsui JI, Cheng DM, Quinn EK, Armah KA, Nunes D, et al. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res Hum Retroviruses 2013; 29:1110 1116.
71. van Tol EA, Holt L, Li FL, Kong FM, Rippe R, Yamauchi M, et al. Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol 1999; 277:G245 G255.
72. Walton KL, Holt L, Sartor RB. Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 2009; 296:G601 G611.
73. Gazzola L, Tincati C, Bellistri GM, Monforte A, Marchetti G. The absence of CD4R T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328 337.
74. Lozupone CA, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 2013; 14:329 339.
75. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra191.
76. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009; 5:e1000295.
77. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32ra36